Eyenovia re-acquires development, commercialization rights to MicroPine in US, Canada
January 16th 2024According to the company, MicroPine, currently in late phase III for pediatric progressive myopia, will complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007.
Read More
AAO 2023: FundamentalVR and AAO team up for pediatric ophthalmic training VR program
November 3rd 2023The collaboration, fueled by a $5 million donation from Knights Templar Eye Foundation (KTEF), will introduce a free and open VR simulation program for ophthalmologists and trainees worldwide.
Read More
Study: Few children – especially those with safety-net insurance – get vision checked at checkups
August 24th 2023According to researchers from University of Michigan and Duke University, children with Medicaid or other public insurance are far less likely than those with private insurance to have had a vision check in the last year at a primary care office.
Read More
Alkeus announces funding and the appointment of Joshua Boger to executive chairman
June 7th 2023The $150 Million Series B funding will allow for the registration and launch of gilderuretinol, the first and only medicine in clinical development to address the underlying mechanism of Stargardt disease.
Read More
Researchers zero in on protecting the vision of premature babies
May 8th 2023Scientists at Medical College of Georgia demonstrated in their animal model of retinopathy of prematurity that the small molecule K604, which is being explored in cancer and Alzheimer’s, can block the development of leaky, obstructive blood vessels in the retina, tamp down inflammation and enable more normal blood vessel growth
Read More